Type 1 Gastric Neuroendocrine Tumor Found on Endoscopic Polypectomy

Abstract

Gastric neuroendocrine tumors (GNET) are rare gastric neoplasms accounting for <1% of all gastric neoplasms. The World Health Organization (WHO) categorized these neoplasms as types 1-3 to help predict malignant potential and long-term survival and guide management. Improved outcomes have been shown with endoscopic resections, but further studies are needed to confirm the best approach. We present a case of a 56-year-old woman who demonstrated the classic features of type one GNET with mucosal and submucosal involvement in the setting of primary atrophic gastritis, secondary hypergastrinemia, and underlying pernicious anemia. In general, standardizing treatment has been difficult due to a variable presentation.

An unusual association of folic acid deficiency with gastric neuroendocrine tumor type I

“…Gastrin binds to the colecystokinin2 (CCK-2) receptor on the ECL cells, determining hyperplasia and subsequently the development of G-NET type 1. 2,4 Also, the destruction of parietal cells in the long-term evolution of atrophic gastritis can lead to decreased intrinsic factor secretion and, consequently, decreased absorption of vitamin B12. Thus, vitamin B12 deficiency and macrocytic hyperchromic anaemia are frequently associated with autoimmune gastritis and hypergastrinemia, but only 5% of people with chronic atrophic gastritis develop G-NET.…”

Gastric Neuroendocrine Tumor

“…Octreoscan is a technetium-based somatostatin scintigraphy test with a high sensitivity and specificity. 9 A recently developed gallium-labeled octreotide captured by positron emission tomography scans shows superiority over the octreotide scintigraphy. 2 …”